Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

Li Shen, Roberto Pili

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Regulatory T cells (Tregs) represent a major obstacle of cancer immunotherapy. We reviewed here our discovery that Class I histone deacetylase (HDAC) inhibition can functionally target Tregs and help break the immune tolerance. We also discuss the effects of different classes of HDAC inhibitors on Tregs and the underline mechanisms, which may have a direct impact on designing cancer immunotherapy trials involving HDAC inhibitors.

Original languageEnglish (US)
Pages (from-to)948-950
Number of pages3
JournalOncoImmunology
Volume1
Issue number6
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Histone Deacetylases
Regulatory T-Lymphocytes
Immunotherapy
Immune Tolerance
Neoplasms

Keywords

  • Foxp3
  • HDAC inhibitors
  • Immunotherapy
  • Regulatory T cells
  • STAT3

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. / Shen, Li; Pili, Roberto.

In: OncoImmunology, Vol. 1, No. 6, 2012, p. 948-950.

Research output: Contribution to journalArticle

@article{a7419438e2534571b089d15c3bac65c1,
title = "Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy",
abstract = "Regulatory T cells (Tregs) represent a major obstacle of cancer immunotherapy. We reviewed here our discovery that Class I histone deacetylase (HDAC) inhibition can functionally target Tregs and help break the immune tolerance. We also discuss the effects of different classes of HDAC inhibitors on Tregs and the underline mechanisms, which may have a direct impact on designing cancer immunotherapy trials involving HDAC inhibitors.",
keywords = "Foxp3, HDAC inhibitors, Immunotherapy, Regulatory T cells, STAT3",
author = "Li Shen and Roberto Pili",
year = "2012",
doi = "10.4161/onci.20306",
language = "English (US)",
volume = "1",
pages = "948--950",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

AU - Shen, Li

AU - Pili, Roberto

PY - 2012

Y1 - 2012

N2 - Regulatory T cells (Tregs) represent a major obstacle of cancer immunotherapy. We reviewed here our discovery that Class I histone deacetylase (HDAC) inhibition can functionally target Tregs and help break the immune tolerance. We also discuss the effects of different classes of HDAC inhibitors on Tregs and the underline mechanisms, which may have a direct impact on designing cancer immunotherapy trials involving HDAC inhibitors.

AB - Regulatory T cells (Tregs) represent a major obstacle of cancer immunotherapy. We reviewed here our discovery that Class I histone deacetylase (HDAC) inhibition can functionally target Tregs and help break the immune tolerance. We also discuss the effects of different classes of HDAC inhibitors on Tregs and the underline mechanisms, which may have a direct impact on designing cancer immunotherapy trials involving HDAC inhibitors.

KW - Foxp3

KW - HDAC inhibitors

KW - Immunotherapy

KW - Regulatory T cells

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84886943464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886943464&partnerID=8YFLogxK

U2 - 10.4161/onci.20306

DO - 10.4161/onci.20306

M3 - Article

AN - SCOPUS:84886943464

VL - 1

SP - 948

EP - 950

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 6

ER -